What does PHARMACIE CRUNENBERG-GILLET do?

PHARMACIE CRUNENBERG-GILLET is a pharmacy in Stavelot. Private Limited, started on 20 March 2012, 1 establishment.

What is the address of PHARMACIE CRUNENBERG-GILLET?

The registered office of PHARMACIE CRUNENBERG-GILLET is located at Les Closures 1 box a, 4970 Stavelot.

Is PHARMACIE CRUNENBERG-GILLET still active?

Yes. According to the CBE (31 October 2026) PHARMACIE CRUNENBERG-GILLET is active, legal situation “Normale toestand”, started on 20 March 2012.

Is PHARMACIE CRUNENBERG-GILLET registered on Peppol?

Yes, PHARMACIE CRUNENBERG-GILLET is registered on the Peppol network with ID 0208:0844540101.

What is the enterprise number of PHARMACIE CRUNENBERG-GILLET?

The enterprise number of PHARMACIE CRUNENBERG-GILLET is BE0844540101.

When was PHARMACIE CRUNENBERG-GILLET founded?

PHARMACIE CRUNENBERG-GILLET was founded on 20 March 2012.

Who are the directors of PHARMACIE CRUNENBERG-GILLET?

According to the 2025 annual accounts, the directors of PHARMACIE CRUNENBERG-GILLET are: Robin CRUNENBERG, Aline GILLET.

Is PHARMACIE CRUNENBERG-GILLET a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 20 March 2012; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMACIE CRUNENBERG-GILLET make in 2025?

PHARMACIE CRUNENBERG-GILLET posted a profit after taxes of € 166,767 in financial year 2025.

What is the revenue of PHARMACIE CRUNENBERG-GILLET?

As a small company, PHARMACIE CRUNENBERG-GILLET is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 553,685.

How much does an employee at PHARMACIE CRUNENBERG-GILLET earn?

The average wage cost per full-time employee at PHARMACIE CRUNENBERG-GILLET was € 57,200 in 2025: staff costs of € 120,161 for 2.1 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMACIE CRUNENBERG-GILLET have?

According to the 2025 annual accounts, PHARMACIE CRUNENBERG-GILLET has 2.1 full-time equivalents (FTE).

PHARMACIE CRUNENBERG-GILLET (Private Limited) - Stavelot

Dossier PHARMACIE CRUNENBERG-GILLET, printed on 31 October 2026 from databakkes.be/en/0844540101/pharmacie-crunenberg-gillet. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

PHARMACIE CRUNENBERG-GILLET from Stavelot, company number BE0844540101, closed financial year 2025 with a result of € 166,767 after tax. For that financial year PHARMACIE CRUNENBERG-GILLET recorded a gross margin of € 553,685 and equity of € 616,075. Compared with financial year 2024, the result moved from € 139,770 to € 166,767. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 24, 2026.

What it is worth Growing

€ 616,075

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 166,767

▲ 19% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 553,961

▲ 24% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 100,666 paid out

60 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

2.1

▼ 0.2 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 120,161

▼ 6% vs 2024

€ 57,200 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 73,534

▼ 41% vs 2024

Of which on lease € 43,955.

Debts at end 2025

Bank debt ≈ 11 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.2 million

▼ 7% vs 2024

€ 104,573 is repaid this year. At this pace the long-term loan is gone in ≈ 11 years.

Owed to suppliers

€ 57,141

▼ 30% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 66,115

▲ 70% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 305,556 Gross margin 2022: € 305,556 First fiscal year in the series	€ 418,823 Gross margin 2023: € 418,823 ▲ 37% vs 2022 (€ 305,556) Favourable step	€ 518,060 Gross margin 2024: € 518,060 ▲ 24% vs 2023 (€ 418,823) Favourable step	€ 553,685 Gross margin 2025: € 553,685 ▲ 7% vs 2024 (€ 518,060) Favourable step	▲ 7%
Profit after taxes	€ 111,876 Profit after taxes 2022: € 111,876 First fiscal year in the series	€ 135,513 Profit after taxes 2023: € 135,513 ▲ 21% vs 2022 (€ 111,876) Favourable step	€ 139,770 Profit after taxes 2024: € 139,770 ▲ 3% vs 2023 (€ 135,513) Favourable step	€ 166,767 Profit after taxes 2025: € 166,767 ▲ 19% vs 2024 (€ 139,770) Favourable step	▲ 19%
Equity	€ 322,062 Equity 2022: € 322,062 First fiscal year in the series	€ 425,910 Equity 2023: € 425,910 ▲ 32% vs 2022 (€ 322,062) Favourable step	€ 554,922 Equity 2024: € 554,922 ▲ 30% vs 2023 (€ 425,910) Favourable step	€ 616,075 Equity 2025: € 616,075 ▲ 11% vs 2024 (€ 554,922) Favourable step	▲ 11%
Total debts	€ 1,538,467 Total debts 2022: € 1,538,467 First fiscal year in the series	€ 1,760,841 Total debts 2023: € 1,760,841 ▲ 14% vs 2022 (€ 1,538,467) Unfavourable step	€ 1,584,653 Total debts 2024: € 1,584,653 ▼ 10% vs 2023 (€ 1,760,841) Favourable step	€ 1,454,098 Total debts 2025: € 1,454,098 ▼ 8% vs 2024 (€ 1,584,653) Favourable step	▼ 8%
Cash	€ 227,456 Cash 2022: € 227,456 First fiscal year in the series	€ 243,999 Cash 2023: € 243,999 ▲ 7% vs 2022 (€ 227,456) Favourable step	€ 447,654 Cash 2024: € 447,654 ▲ 83% vs 2023 (€ 243,999) Favourable step	€ 553,961 Cash 2025: € 553,961 ▲ 24% vs 2024 (€ 447,654) Favourable step	▲ 24%
Land & buildings	€ 946,545 Land & buildings 2022: € 946,545 First fiscal year in the series	€ 997,309 Land & buildings 2023: € 997,309 ▲ 5% vs 2022 (€ 946,545) Unchanged	€ 944,979 Land & buildings 2024: € 944,979 ▼ 5% vs 2023 (€ 997,309) Unchanged	€ 892,650 Land & buildings 2025: € 892,650 ▼ 6% vs 2024 (€ 944,979) Unchanged	▼ 6%
Retained profit	€ 247,062 Retained profit 2022: € 247,062 First fiscal year in the series	€ 350,910 Retained profit 2023: € 350,910 ▲ 42% vs 2022 (€ 247,062) Favourable step	€ 479,922 Retained profit 2024: € 479,922 ▲ 37% vs 2023 (€ 350,910) Favourable step	€ 541,075 Retained profit 2025: € 541,075 ▲ 13% vs 2024 (€ 479,922) Favourable step	▲ 13%
Dividend	€ 37,600 Dividend 2022: € 37,600 First fiscal year in the series	€ 31,666 Dividend 2023: € 31,666 ▼ 16% vs 2022 (€ 37,600) Unchanged	€ 7,666 Dividend 2024: € 7,666 ▼ 76% vs 2023 (€ 31,666) Unchanged	€ 100,666 Dividend 2025: € 100,666 ▲ € 93,000 vs 2024 (€ 7,666) Unchanged	▲ € 93,000
Bank debt	€ 1,289,435 Bank debt 2022: € 1,289,435 First fiscal year in the series	€ 1,383,643 Bank debt 2023: € 1,383,643 ▲ 7% vs 2022 (€ 1,289,435) Unfavourable step	€ 1,286,534 Bank debt 2024: € 1,286,534 ▼ 7% vs 2023 (€ 1,383,643) Favourable step	€ 1,190,850 Bank debt 2025: € 1,190,850 ▼ 7% vs 2024 (€ 1,286,534) Favourable step	▼ 7%
Balance sheet total	€ 1,860,529 Balance sheet total 2022: € 1,860,529 First fiscal year in the series	€ 2,186,751 Balance sheet total 2023: € 2,186,751 ▲ 18% vs 2022 (€ 1,860,529) Unchanged	€ 2,139,574 Balance sheet total 2024: € 2,139,574 ▼ 2% vs 2023 (€ 2,186,751) Unchanged	€ 2,070,173 Balance sheet total 2025: € 2,070,173 ▼ 3% vs 2024 (€ 2,139,574) Unchanged	▼ 3%
Employees (FTE)	1.1 Employees (FTE) 2022: 1.1 First fiscal year in the series	1.5 Employees (FTE) 2023: 1.5 ▲ 0.4 vs 2022 (1.1) Unchanged	2.3 Employees (FTE) 2024: 2.3 ▲ 0.8 vs 2023 (1.5) Unchanged	2.1 Employees (FTE) 2025: 2.1 ▼ 0.2 vs 2024 (2.3) Unchanged	▼ 0.2

Key figures of PHARMACIE CRUNENBERG-GILLET, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMACIE CRUNENBERG-GILLET?

What happened at PHARMACIE CRUNENBERG-GILLET in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 24, 2026 New annual accounts for financial year 2025: profit of € 166,767 (▲ 19% vs 2024). Source: NBB ↗
Jul 1, 2012 New establishment in Stavelot. KBO
Mar 20, 2012 Start of the company according to the CBE. KBO

In short

From € 111,876 profit in 2022 to € 166,767 profit in 2025.

Paid € 173,068 in corporate taxes since 2022.

Best year ever: 2025, with € 166,767 profit.

On average € 263,700 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Robin CRUNENBERG Aline GILLET

PHARMACIE CRUNENBERG-GILLET

Behind PHARMACIE CRUNENBERG-GILLET are Robin CRUNENBERG and Aline GILLET.

Directors

According to the 2025 annual accounts

Robin CRUNENBERG

Director

Aline GILLET

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Les Closures 1 box a

4970 Stavelot

2.209.763.334

Avenue du Doyard 9 box 4

4970 Stavelot

Active since 1 July 2012

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0844.540.101
VAT number: BE 0844.540.101
Registered office: Les Closures 1 bus a, 4970 Stavelot
Names & denominations: PHARMACIE CRUNENBERG-GILLET
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 20 March 2012
Peppol: Active · Active since 19 Nov 2025
Activities · NACE: Detailhandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗